Coronavirus Hasn’t Hurt Drug Supply, but That Could Change

Industry experts say the COVID-19 outbreak is unlikely to limit U.S. drug supplies in the short or middle term. However, they tell AIS Health that increased demand for longer-duration stocks of medication from self-isolating patients could strain supplies going forward.

“We are told at this point that we’re not seeing any [drug] shortages in the marketplace today,” Kelly McGrail-Pokuta, Prime Therapeutics’ vice president of pharmaceutical trade, told AIS Health on March 10.

© 2021 MMIT

Peter Johnson

Peter has been a reporter for nearly a decade. Before joining AIS Health, Peter covered a wide variety of topics in his hometown of Seattle, where he continues to live. Peter’s work has appeared in publications including The Atlantic and The Stranger. Peter attended Colby College.

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/WordPress-Featured-Image-radar-on-drug-benefits-Experts-EU-Will-Continue-to-Beat-US-on-Biosimilar-Adoption.jpg
September 23

Experts: EU Will Continue to Beat US on Biosimilar Adoption

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/WordPress-Featured-Image-radar-on-drug-benefits-Pharma-Industry-Braces-as-Dems-Hash-Out-Drug-Price-Package.jpg
September 23

Pharma Industry Braces as Dems Hash Out Drug Price Package

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/WordPress-Featured-Image-radar-on-drug-benefits-Study-Flags-Potential-Benefit-of-Targeted-Medication-Reviews.jpg
September 23

Study Flags Potential Benefit of Targeted Medication Reviews

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today